about
CB2 Cannabinoid Receptor As Potential Target against Alzheimer's DiseaseDNA methylation map of mouse and human brain identifies target genes in Alzheimer's disease.Essential role of the N-terminal region of TFII-I in viability and behavior.Amyotrophic lateral sclerosis, gene deregulation in the anterior horn of the spinal cord and frontal cortex area 8: implications in frontotemporal lobar degenerationPromoter hypermethylation of the phosphatase DUSP22 mediates PKA-dependent TAU phosphorylation and CREB activation in Alzheimer's disease.Complex Inflammation mRNA-Related Response in ALS Is Region DependentGenetically modified mice as tools to understand the neurobiological substrates of depression.Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic.An early dysregulation of FAK and MEK/ERK signaling pathways precedes the β-amyloid deposition in the olfactory bulb of APP/PS1 mouse model of Alzheimer's disease.Shared changes in gene expression in frontal cortex of four genetically modified mouse models of depression.Inflammatory Gene Expression in Whole Peripheral Blood at Early Stages of Sporadic Amyotrophic Lateral Sclerosis.CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice.Altered expression of neuronal tryptophan hydroxylase-2 mRNA in the dorsal and median raphe nuclei of three genetically modified mouse models relevant to depression and anxiety.Involvement of the opioid system in the effects induced by nicotine on anxiety-like behaviour in mice.Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice.Triheptanoin supplementation to ketogenic diet curbs cognitive impairment in APP/PS1 mice used as a model of familial Alzheimer's disease.Neuroinflammatory Gene Regulation, Mitochondrial Function, Oxidative Stress, and Brain Lipid Modifications With Disease Progression in Tau P301S Transgenic Mice as a Model of Frontotemporal Lobar Degeneration-Tau.Neuroinflammatory signals in Alzheimer disease and APP/PS1 transgenic mice: correlations with plaques, tangles, and oligomeric species.CB1 knockout mice display impaired functionality of 5-HT1A and 5-HT2A/C receptors.Fibrinogen-Derived γ377-395 Peptide Improves Cognitive Performance and Reduces Amyloid-β Deposition, without Altering Inflammation, in AβPP/PS1 Mice.Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations.Locus coeruleus at asymptomatic early and middle Braak stages of neurofibrillary tangle pathology.Genes differentially expressed in CB1 knockout mice: involvement in the depressive-like phenotype.The cannabis paradox: when age matters.Evidence for premature lipid raft aging in APP/PS1 double-transgenic mice, a model of familial Alzheimer disease.Cerebellar amyloid-β plaques: disturbed cortical circuitry in AβPP/PS1 transgenic mice as a model of familial Alzheimer's disease.FOXP2 Expression in Frontotemporal Lobar Degeneration-Tau.CB1 agonist ACEA protects neurons and reduces the cognitive impairment of AβPP/PS1 mice.Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice.Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial Alzheimer's disease.Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine.Chronic stress and impaired glutamate function elicit a depressive-like phenotype and common changes in gene expression in the mouse frontal cortex.Effect of poly(propylene imine) glycodendrimers on beta-amyloid aggregation in vitro and in APP/PS1 transgenic mice, as a model of brain amyloid deposition and Alzheimer's disease.Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model.Novel Levetiracetam Derivatives That Are Effective against the Alzheimer-like Phenotype in Mice: Synthesis, in Vitro, ex Vivo, and in Vivo Efficacy Studies.Memory Improvement in the AβPP/PS1 Mouse Model of Familial Alzheimer’s Disease Induced by Carbamylated-Erythropoietin is Accompanied by Modulation of Synaptic Genes.Neuronal hemoglobin is reduced in Alzheimer's disease, argyrophilic grain disease, Parkinson's disease, and dementia with Lewy bodies.PPARγ agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer's disease: in vitro and in vivo studiesCannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous systemPoly(propylene imine) dendrimers with histidine-maltose shell as novel type of nanoparticles for synapse and memory protection
P50
Q26746050-18FD9738-112E-4D09-A18C-5092FB012E05Q30009564-5C5EA12F-235A-4089-806A-94BF840BCC51Q30481565-5CC64446-AB14-465F-BDED-C906150A15ECQ33563621-3842455D-32BF-46A3-89EC-9C72A18D4439Q34522096-3682B1DA-C9E3-444E-88B2-92D18C46DB12Q35957868-C4176E31-5884-4980-9933-5856C997BC40Q38158124-DFFE2944-633E-42FF-8335-C4A269022955Q38196398-532E5AA8-7CB9-4FA0-B5F8-858315CA7F79Q38291385-FB28375C-7158-43A5-A8A9-C24EF17814C8Q38504564-F79CA7CA-D366-416C-9314-C2A0D697AD46Q42683273-6CEBAADA-98BB-4E9D-9579-0776DFA860BFQ44094824-E6B07ED2-E59C-4C53-AD90-4F39764AA62BQ44183601-4ECBED92-5E20-423D-96A3-74FD7B95ECD2Q44348416-FFE14F35-FA8A-42A1-8062-FD1C59F0F9F1Q45153251-9F2F1BFD-270F-4DAC-85D8-D991C38F2DD6Q46056482-4A91B1EE-D209-4FE7-9C01-145B54D63C69Q46671150-1B9310B0-DE32-4F03-B55C-2954FAD1C5CCQ46761900-4FE49376-C409-4D05-B4F9-AD56998616D7Q46943465-D5B54433-12ED-48C1-A289-B94822825154Q47612205-00106371-9229-454A-A322-6904B399BE2FQ47914487-A01B1FBD-F2F1-4F0D-8456-7827A3D31121Q47986956-1929D9B6-2738-45E1-8EEA-F830A1F7E773Q48097060-5A96E49D-7612-4558-8343-6CDACEA4511EQ48320513-C94836BD-30C3-4577-86E4-7CA785C332F2Q48377897-69FDF886-695D-45E9-8F86-CEB7FB728A1FQ48530053-711201CC-B71B-48D5-AE2D-94D364D70DD9Q48585121-7090BD9B-795A-48AF-9D4C-9E061CB6E59DQ48596005-54AD087D-8A79-4987-AEFD-66E0936872B5Q48603101-2CAA93E6-9282-4528-A674-03E537D41B7BQ48762970-D7530F8D-12FE-4AB4-91CC-B691C0012949Q48895791-38A0B49A-29CD-49FE-B510-13A2DF05EF4FQ49012204-5B8DAFDA-14FB-468F-99CA-AD29B20CEF23Q49076009-02fa869a-474b-f85f-5f59-f768530d5664Q50230005-45DD20AF-811A-48BD-9C9A-732D3C9CC8DDQ50440283-34F81336-08E1-4FA3-8C78-F703FA8F5310Q50746046-60F4C149-F335-43A9-9A89-3BAF5F1497BFQ53315253-13B51FC0-01D0-4610-A1EC-45D832090BD9Q57071932-223F50DC-6DA3-4962-811D-AFC3AF1C9E43Q57168673-71EF6963-872E-48DF-A1D3-93522BA6DCDBQ70830880-A9C4E212-D030-47E6-9B44-6E7ACA83789A
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ester Aso
@ast
Ester Aso
@en
Ester Aso
@es
Ester Aso
@nl
Ester Aso
@sl
type
label
Ester Aso
@ast
Ester Aso
@en
Ester Aso
@es
Ester Aso
@nl
Ester Aso
@sl
prefLabel
Ester Aso
@ast
Ester Aso
@en
Ester Aso
@es
Ester Aso
@nl
Ester Aso
@sl
P1053
K-4484-2014
P106
P21
P31
P3829
P496
0000-0003-1836-1747